Anacetrapib as a potential cardioprotective strategy

References

• BarterPJChapmanMJHennekensCHRaderDJTallARCholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosisArterioscler Thromb Vasc Biol2003232 160 16712588754
   PubMed Web of Science ®Google Scholar
• BrousseauMESchaeferEJWolfeMLEffects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterolN Engl J Med200435015 1505 151515071125
   PubMed Web of Science ®Google Scholar
• RittershausCWMillerDPThomasLJVaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosisArterioscler Thromb Vasc Biol2000209 2106 211210978256
   PubMed Web of Science ®Google Scholar
• SuganoMMakinoNSawadaSEffect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbitsJ Biol Chem19982739 5033 50369478952
   PubMed Web of Science ®Google Scholar
• OkamotoHYonemoriFWakitaniKMinowaTMaedaKShinkaiHA cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbitsNature20004066792 203 20710910363
   PubMed Web of Science ®Google Scholar
• MorehouseLASugarmanEDBourassaPAInhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbitsJ Lipid Res2007486 1263 127217325387
   PubMed Web of Science ®Google Scholar
• ThompsonADi AngelantonioESarwarNAssociation of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary riskJAMA200829923 2777 278818560005
   PubMed Web of Science ®Google Scholar
• JohannsenTHFrikke-SchmidtRSchouJNordestgaardBGTybjaerg-HansenAGenetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effectsJ Am Coll Cardiol20126020 2041 204823083790
   PubMed Web of Science ®Google Scholar
• BarterPJCaulfieldMErikssonMILLUMINATE InvestigatorsEffects of torcetrapib in patients at high risk for coronary eventsN Engl J Med200735721 2109 212217984165
   PubMed Web of Science ®Google Scholar
• NissenSETardifJCNichollsSJILLUSTRATE InvestigatorsEffect of torcetrapib on the progression of coronary atherosclerosisN Engl J Med200735613 1304 131617387129
   PubMed Web of Science ®Google Scholar
• BotsMLVisserenFLEvansGWRADIANCE 2 InvestigatorsTorcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trialLancet20073709582 153 16017630038
   PubMed Web of Science ®Google Scholar
• KasteleinJJvan LeuvenSIBurgessLRADIANCE 1 InvestigatorsEffect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemiaN Engl J Med200735616 1620 163017387131
   PubMed Web of Science ®Google Scholar
• Yvan-CharvetLMatsuuraFWangNInhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDLArterioscler Thromb Vasc Biol2007275 1132 113817322101
   PubMed Web of Science ®Google Scholar
• NichollsSJTuzcuEMBrennanDMTardifJCNissenSECholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)Circulation200811824 2506 251419029466
   PubMed Web of Science ®Google Scholar
• BarterPLessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trialAm J Cardiol200910410 Suppl 10E 15E
   PubMed Web of Science ®Google Scholar
• VergeerMStroesESThe pharmacology and off-target effects of some cholesterol ester transfer protein inhibitorsAm J Cardiol200910410 Suppl 32E 38E
   PubMed Web of Science ®Google Scholar
• LüscherTFTaddeiSKaskiJCdal-VESSEL InvestigatorsVascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trialEur Heart J2012337 857 86522345126
   PubMed Web of Science ®Google Scholar
• FayadZAManiVWoodwardMdal-PLAQUE InvestigatorsSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trialLancet20113789802 1547 155921908036
   PubMed Web of Science ®Google Scholar
• SchwartzGGOlssonAGAbtMdal-OUTCOMES InvestigatorsEffects of dalcetrapib in patients with a recent acute coronary syndromeN Engl J Med201236722 2089 209923126252
   PubMed Web of Science ®Google Scholar
• TardifJCRhéaumeELemieux PerreaultLPPharmacogenomic determinants of the cardiovascular effects of dalcetrapibCirc Cardiovasc Genet201582 372 38225583994
   PubMed Web of Science ®Google Scholar
• NichollsSJBrewerHBKasteleinJJEffects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trialJAMA201130619 2099 210922089718
   PubMed Web of Science ®Google Scholar
• LincoffAMNichollsSJRiesmeyerJSACCELERATE InvestigatorsEvacetrapib and cardiovascular outcomes in high-risk vascular diseaseN Engl J Med201737620 1933 194228514624
   PubMed Web of Science ®Google Scholar
• NichollsSJRayKKBallantyneCMACCENTUATE InvestigatorsComparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the ACCENTUATE trialAtherosclerosis2017261 12 1828412650
   PubMed Web of Science ®Google Scholar
• CannonCPShahSDanskyHMDetermining the Efficacy and Tolerability InvestigatorsSafety of anacetrapib in patients with or at high risk for coronary heart diseaseN Engl J Med201036325 2406 241521082868
   PubMed Web of Science ®Google Scholar
• ForrestMJBloomfieldDBriscoeRJTorcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosteroneBr J Pharmacol20081547 1465 147318536749
   PubMed Web of Science ®Google Scholar
• KühnastSvan der TuinSJvan der HoornJWAnacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatinEur Heart J2015361 39 4825142968
   PubMed Web of Science ®Google Scholar
• SimicBMocharlaPCrucetMAnacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increaseAtherosclerosis2017257 186 19428152406
   PubMed Web of Science ®Google Scholar
• KrishnaRGheyasFLiuYChronic administration of anacetrapib is associated with accumulation in adipose and slow eliminationClin Pharmacol Ther20171025 832 84028380664
   PubMed Web of Science ®Google Scholar
• Castro-PerezJBriandFGagenKAnacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamstersJ Lipid Res20115211 1965 197321841206
   PubMed Web of Science ®Google Scholar
• WuBJShresthaSOngKLCholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbitArterioscler Thromb Vasc Biol2015353 628 63625633313
   PubMed Web of Science ®Google Scholar
• WuBJShresthaSOngKLIncreasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesisInt J Cardiol2015199 204 21226204569
   PubMed Web of Science ®Google Scholar
• Reyes-SofferGMillarJSNgaiCCholesteryl ester transfer protein inhibition with anacetrapib decreases fractional clearance rates of high-density lipoprotein apolipoprotein A-I and plasma cholesteryl ester transfer proteinArterioscler Thromb Vasc Biol2016365 994 100226966279
   PubMed Web of Science ®Google Scholar
• MillarJSReyes-SofferGJumesPAnacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjectsJ Clin Invest20151256 2510 252225961461
   PubMed Web of Science ®Google Scholar
• MillarJSLassmanMEThomasTEffects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and EJ Lipid Res2017586 1214 122028314859
   PubMed Web of Science ®Google Scholar
• ThomasTZhouHKarmallyWCETP (cholesteryl ester transfer protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjectsArterioscler Thromb Vasc Biol2017379 1770 177528729361
   PubMed Web of Science ®Google Scholar
• KasteleinJJBesselingJShahSAnacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 studyLancet20153859983 2153 216125743173
   PubMed Web of Science ®Google Scholar
• GottoAMJrKherUChatterjeeMSDEFINE InvestigatorsLipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE studyJ Cardiovasc Pharmacol Ther2014196 543 54924737712
   PubMed Web of Science ®Google Scholar
• HPS3/TIMI55–REVEAL Collaborative GroupBowmanLHopewellJCChenFEffects of anacetrapib in patients with atherosclerotic vascular diseaseN Engl J Med201737713 1217 122728847206
   PubMed Web of Science ®Google Scholar
• FerenceBAKasteleinJJPGinsbergHNAssociation of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular riskJAMA201731810 947 95628846118
   PubMed Web of Science ®Google Scholar